Your browser doesn't support javascript.
loading
The Significance of Para-Aortic Nodal Size and the Role of Adjuvant Systemic Chemotherapy in Cervical Cancer: An Institutional Experience.
Manders, Dustin B; Sims, Travis T; Bailey, April; Hwang, Lindsay; Richardson, Debra L; Miller, David S; Kehoe, Siobhan M; Albuquerque, Kevin V; Lea, Jayanthi S.
Afiliação
  • Manders DB; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology.
  • Sims TT; Departments of Obstetrics and Gynecology.
  • Bailey A; Departments of Obstetrics and Gynecology.
  • Hwang L; Radiology.
  • Richardson DL; Radiology.
  • Miller DS; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology.
  • Kehoe SM; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology.
  • Albuquerque KV; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology.
  • Lea JS; Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX.
Am J Clin Oncol ; 41(12): 1225-1230, 2018 12.
Article em En | MEDLINE | ID: mdl-29782361
ABSTRACT

OBJECTIVE:

Cervical cancer metastatic to the para-aortic lymph nodes (PALNs) carries a poor prognosis. Despite extended-field radiation therapy (EFRT), only 30% to 50% of patients will survive 3 years. We sought to examine the treatment regimens used, associated toxicities, and treatment outcomes in patients with cervical cancer metastatic to PALN.

METHODS:

A retrospective review was performed of all patients with cervical cancer treated at a single institution between January 1, 2007 and November 1, 2014. Included patients had PALN metastases as the most distant site of disease, and all treatment plans were designated as curative. Excluded patients had other distant disease or treatment plans considered palliative. Standard treatment consisted of EFRT with concurrent platinum-based chemotherapy.

RESULTS:

Fifty-one of 344 patients (14.8%) fulfilled the inclusion criteria. The median age was 48.4 years. Forty-four patients received standard EFRT; 7 also received adjuvant platinum/taxane chemotherapy. Thirty-nine of 51 (76%) of patients achieved a complete response to primary treatment. Twelve of 51 (24%) had persistent disease or progression at the completion of treatment. Of responders, 15 of 39 (38%) recurred for an overall treatment failure rate of 27 of 51 (53%). Nineteen of 27 (70%) of treatment failures occurred outside the radiated field. Adjuvant chemotherapy following EFRT was not predictive of progression-free survival or overall survival. PALN diameter ≥1 cm was a significant negative prognostic indicator for overall survival.

CONCLUSIONS:

Over half of patients with cervical cancer metastatic to the PALN failed extended-field chemoradiation. Most failures occurred outside the radiated field suggesting PALN involvement is a surrogate marker of systemic disease. These findings underscore the need for effective systemic therapy, especially in patients with PALN ≥1 cm in size.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma de Células Escamosas / Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias do Colo do Útero / Quimioterapia Adjuvante / Quimiorradioterapia / Linfonodos Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma de Células Escamosas / Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias do Colo do Útero / Quimioterapia Adjuvante / Quimiorradioterapia / Linfonodos Idioma: En Ano de publicação: 2018 Tipo de documento: Article